MARKET WIRESimply Wall St • 1d ago
cbdMD (NYSEAM:YCBD) - Stock AnalysisSimply Wall St report covering cbdMD Inc. (YCBD) market action, institutional positioning, and fundamental catalysts.
Why YCBD Stock surged +3.66% Today — RQD Quant Desk Flash
$0.40 +3.66% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $0.40
cbdMD Inc. (YCBD) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $4.4M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on YCBD Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is YCBD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, cbdMD Inc. (NYSE: YCBD) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $0.40 (+3.66% 1D, market cap $4.4M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 5/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does YCBD compare to BYAH and BNKK in the Consumer Discretionary sector?
▼
Within the Consumer Discretionary sector (Package Goods/Cosmetics), YCBD carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of 62.4%, and ROIC of -30.4%. By comparison, BYAH (Park Ha Biological Technology Co. Ltd. (Class A)) holds a D- grade (43/100 RQD, P/E N/A, ROIC —, cap $6.6M) and BNKK (Bonk Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $8.4M). Among the 5-stock peer group, UG leads on earnings multiple (14.5x) while UG leads on capital efficiency (17.8% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for YCBD?
▼
Per YCBD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001644903), cbdMD Inc. generated $19.2M in revenue (-1.5% YoY), -$2.0M in net income, and -$1.6M in free cash flow against $11.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Consumer Discretionary with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $0.40 (+0.47%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR RQD RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-10% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for YCBD)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (36/100 Composite)
🔍 WHY YCBD SCORES 36/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (28% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9
▲ #2 Bullish Driver: Whale & Options Positioning+9/20 pts (25% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$0.35+8.6% Next Q
28
Q2 (-2Q)Grade E$0.38-2.6% Next Q
31
Q3 (-1Q)Grade E$0.37+8.1% Next Q
33
CurrentGrade D-$0.40-8.3% Hist 90D α
36
Trajectory: E (28) → D- (36)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a YCBD Turnaround Squeeze
While YCBD currently carries a cautious 36/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Consumer Discretionary with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.43) and Max Pain ($0.42) forces dealer call-delta covering toward $2.69.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $YCBD• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “YCBD Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why YCBD Stock surged +3.66% Today — RQD Quant Desk Flash
cbdMD Inc. (YCBD) surged +3.66% to $0.40, trading at 3% of its 52-week range ($0.33 – $2.56). Stretched risk/reward at current multiples (-30% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 3% of its 52-week range ($0.33 – $2.56) with RSI-14 at 50.9 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.40 (no active unusual options sweep snapshot on file).
- ▸Primary SEC / Cross-Feed Trigger: YCBD Exhibits 4.17x True Net Liquidity Elasticity as Fed-TGA-RRP Prints $5,746B
Live YCBD Headlines & Catalysts
MARKET WIREcbdMD • 1d ago
October is National Pet CBD MonthcbdMD report covering cbdMD Inc. (YCBD) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 2d ago
cbdMD, Inc. Estimates – AMEX:YCBDTradingView report covering cbdMD Inc. (YCBD) market action, institutional positioning, and fundamental catalysts.
MARKET WIREThe Batesville Daily Guard • 2d ago
cbdMD Completes Acquisition of the Operating Assets and Brands of Twinlab, including Twinlab, Reserveage and Metabolife Brands, Expanding Into Broader WellnessThe Batesville Daily Guard report covering cbdMD Inc. (YCBD) market action, institutional positioning, and fundamental catalysts.
MARKET WIREcbdMD • 2d ago
ABC Stores Bring cbdMD Products to Hawaii and BeyondcbdMD report covering cbdMD Inc. (YCBD) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 6d ago
12 Health Care Stocks Moving In Wednesday's After-Market SessionGainers Lakewood-Amedex (NASDAQ:LABT) stock rose 20.4% to $0.34 during Wednesday's after-market session. Glaukos (NYSE:GKOS) stock rose 16.85% to $212.01. The company's market cap stands at $10.6 billion. As
MARKET WIREBenzinga • 20d ago
12 Health Care Stocks Moving In Thursday's Pre-Market SessionGainers SciSparc (NASDAQ:SPRC) shares moved upwards by 28.9% to $4.68 during Thursday's pre-market session. The market value of their outstanding shares is at $2.2 million. Valion Bio (NASDAQ:VBIO) stock increased
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring YCBD)
- ✓Walkthrough of YCBD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
YCBD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -52.94%▼ DESCENDING CHANNEL
2026-11-04O $0.39H $0.40L $0.39C $0.40VOL 298.5K
RES: $0.53SUP: $0.26SMA50: $0.43SMA200: $0.66
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
YCBD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. -1.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on YCBD today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for YCBD. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for YCBD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (YCBD)
Consumer Discretionary Rank #786 of 1009
⚔️ BYAH vs YCBD Full Matrix →
1. Head-to-Head Consumer Discretionary Peer Comparison (YCBD vs. BYAH, BNKK, CABR, UG)
Industry: Package Goods/Cosmetics (23 Tracked Issuers)Across 1009 tracked Consumer Discretionary securities in the Roarable RQD universe, cbdMD Inc. (YCBD) ranks #786 by composite RQD confidence (36/100, grade D-) and #969 by equity capitalization ($4.4M). Within this direct 5-issuer industry benchmark cohort, UG leads on earnings valuation at 14.5x trailing P/E, while UG leads on capital efficiency and profitability with 17.8% ROIC and — gross margin. UG currently holds the highest overall quantitative score in the immediate peer group at 71/100 (B-) compared with YCBD at 36/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| YCBD
ACTIVE
cbdMD Inc. | D- | 36/100 | — | 62.4% | -30.4% | +3.66% | $4.4M | Benchmark Subject |
| BYAH Park Ha Biological Technology Co. Ltd. (Class A) | D- | 43/100 | — | 94.4% | — | -13.12% | $6.6M | /byah-vs-ycbd → |
| BNKK Bonk Inc. | E | 32/100 | — | 58.5% | -35.0% | -1.85% | $8.4M | /bnkk-vs-ycbd → |
| CABR Caring Brands Inc. | D- | 40/100 | — | 55.6% | -35.0% | -7.96% | $10.9M | /cabr-vs-ycbd → |
| UG United-Guardian Inc. | B- | 71/100 | 14.5x | — | 17.8% | +2.55% | $33.3M | /ug-vs-ycbd → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-09-30 • CIK 0001644903 ↗In its most recent audited fiscal period (FY2025, filed 2025-09-30), cbdMD Inc. (YCBD) reported GAAP revenue of $19.2M (-1.5% vs. FY2024 revenue of $19.5M , and -20.6% cumulative change since FY2023) , GAAP net income of -$2.0M, operating cash flow of -$1.5M, and free cash flow of -$1.6M (-201.5% YoY). On the balance sheet, YCBD closed FY2025 with $11.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-09-30 | $19.2M | -$2.0M | -$1.5M | -$1.6M | $11.8M | — |
| FY2024 (FY) | 2024-09-30 | $19.5M | -$3.7M | -$352.8K | -$542.8K | $11.5M | — |
| FY2023 (FY) | 2023-09-30 | $24.2M | -$22.9M | -$4.3M | -$4.3M | — | — |
3. YCBD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs YCBD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, cbdMD Inc. (NYSE: YCBD) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $0.40 (+3.66% 1D, market cap $4.4M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 5/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.
How does YCBD compare to BYAH and BNKK in the Consumer Discretionary sector?
Within the Consumer Discretionary sector (Package Goods/Cosmetics), YCBD carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of 62.4%, and ROIC of -30.4%. By comparison, BYAH (Park Ha Biological Technology Co. Ltd. (Class A)) holds a D- grade (43/100 RQD, P/E N/A, ROIC —, cap $6.6M) and BNKK (Bonk Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $8.4M). Among the 5-stock peer group, UG leads on earnings multiple (14.5x) while UG leads on capital efficiency (17.8% ROIC).
What are the biggest fundamental strengths and SEC risk factors for YCBD?
Per YCBD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001644903), cbdMD Inc. generated $19.2M in revenue (-1.5% YoY), -$2.0M in net income, and -$1.6M in free cash flow against $11.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Consumer Discretionary with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is YCBD trading relative to its 50-day, 200-day, and 52-week technical levels?
YCBD last traded at $0.40 (+3.66% on volume of 298,500 shares), positioning the stock -6.98% below its 50-day simple moving average ($0.43) and -39.39% below its 200-day simple moving average ($0.66). Across its 52-week range of $0.33 to $2.56, YCBD sits at the 3.1% percentile with a 14-day RSI of 50.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.45).
ROARABLE RATING BRIEF • RQD 36/100 (D-)
✓ SEC XBRL & RQD VERIFIED
YCBD — cbdMD Inc.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-09-30
1. Roarable Rating Brief: What This Means to a Prospective Investor
cbdMD Inc. (YCBD) earns a live Roarable RQD composite score of 36/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $0.40 (+3.66% 1D, market capitalization $4.4M).
- Fundamental Cash Engine (5/20): Anchored by return on invested capital (ROIC) of -30.4%, gross margin of 62.4%, operating margin of -11.3%, and free cash flow yield of —.
- Whale 13F & Options Flow (9/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (7/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 4/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
CbdMD Inc. Is a NYSE-listed issuer in the Consumer Discretionary sector, operating in the Package Goods/Cosmetics industry. It is a NYSE-listed Consumer Discretionary issuer in Package Goods/Cosmetics. Per the recent news wire, the company completed an acquisition of the operating assets and brands of Twinlab, including Twinlab, Reserveage and Metabolife Brands, and announced ABC Stores distribution of cbdMD products.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-09-30), cbdMD Inc. (YCBD) reported $19.2M in annual revenue (up from $19.5M in FY2024, -1.5% YoY) and -$2.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($24.2M revenue, -$22.9M net income) through FY2025, YCBD scaled operating cash flow to -$1.5M and free cash flow to -$1.6M, backed by $11.8M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (D- • RQD 36/100): Established market leader in Consumer Discretionary with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 9/20. With Fundamental Cash Engine at 5/20 and Institutional Whale Flow at 9/20, sustained execution supports upside toward the upper end of the $0.33 – $2.56 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -11.3% operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
A second-order watch item is that a reversal in net liquidity would remove the tailwind from a stock whose fundamentals do not independently support valuation.
- Key Question #1: Can YCBD sustain or expand its -11.3% operating margin and -30.4% ROIC against Package Goods/Cosmetics peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $19.2M and free cash flow of -$1.6M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is YCBD's equity valuation to Consumer Discretionary capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
YCBD Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for cbdMD Inc. (YCBD) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Simply Wall St • 1d ago
cbdMD (NYSEAM:YCBD) - Stock Analysis Simply Wall St report covering cbdMD Inc. (YCBD) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE cbdMD • 1d ago
October is National Pet CBD Month cbdMD report covering cbdMD Inc. (YCBD) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 2d ago
cbdMD, Inc. Estimates – AMEX:YCBD TradingView report covering cbdMD Inc. (YCBD) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE The Batesville Daily Guard • 2d ago
cbdMD Completes Acquisition of the Operating Assets and Brands of Twinlab, including Twinlab, Reserveage and Metabolife Brands, Expanding Into Broader Wellness The Batesville Daily Guard report covering cbdMD Inc. (YCBD) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE cbdMD • 2d ago
ABC Stores Bring cbdMD Products to Hawaii and Beyond cbdMD report covering cbdMD Inc. (YCBD) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Benzinga • 6d ago
12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Lakewood-Amedex (NASDAQ:LABT) stock rose 20.4% to $0.34 during Wednesday's after-market session. Glaukos (NYSE:GKOS) stock rose 16.85% to $212.01. The company's market cap stands at $10.6 billion. As
🟡 MARKET WIRE Benzinga • 20d ago
12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers SciSparc (NASDAQ:SPRC) shares moved upwards by 28.9% to $4.68 during Thursday's pre-market session. The market value of their outstanding shares is at $2.2 million. Valion Bio (NASDAQ:VBIO) stock increased
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
YCBD Bull vs. Bear Conversation Board — What's Your Call at $0.40?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON YCBD 🐻 33% BEARISH CONVICTION
CA CashFlowKing RQD DEBATE OPENER • FCF Compounder Hunter 🐂 BULLISH
🎯 Target: $0.46 (+21.1%)
📌 Pinned Debate The Butterfly liquidity signal rates a 96/100 macro tailwind with a 4.17x net-liquidity elasticity, so the stock could rally sharply if
Long YCBD at $0.38 targeting $0.46. The Butterfly liquidity signal rates a 96/100 macro tailwind with a 4.17x net-liquidity elasticity, so the stock could rally sharply if Fed and Treasury plumbing stays supportive.. Institutional whale score is 9/20 and the risk/reward vs. the $0.33 52-week low is skewed heavily in favor of bulls.
CapAlloc_Nerd 🐂 BULL
@SkepticalCFA Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Package Goods/Cosmetics. If gross margin (62.4%) holds, EPS grows into the multiple faster than bears think.
SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH
🎯 Target: $0.30 (-21.1%)
Spot @ $0.38 With ROIC at -30.4%, FCF yield at 0%, and FY 2025 net income at -$2.0M, the company is not generating the cash needed to support its va
I respect the product at cbdMD Inc., but the stock at $0.38 is a different story. With ROIC at -30.4%, FCF yield at 0%, and FY 2025 net income at -$2.0M, the company is not generating the cash needed to support its valuation.. FCF yield is 0.0% and RQD sits at 36/100 (D-) — why pay up here when you can wait for next quarter's numbers?